Salem Radio Network News Wednesday, May 25, 2022

Health

Eli Lilly expects FDA to decline expanded use of Olumiant for eczema

(Reuters) – Eli Lilly and Co said on Friday it expects the U.S. Food and Drug Administration to decline the approval of expanded use of its rheumatoid arthritis drug Olumiant as a treatment for adults with moderate-to-severe eczema.

“At this point, the company does not have alignment with the FDA on the indicated population,” the drugmaker said.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Krishna Chandra Eluri)

Previous
Next

Editorial Cartoons

View More »

Michael Ramirez
Thu, May 19, 2022

X CLOSE